Joe Skraba, Entvantage DX, at the Fall Startup and Venture Capital Summit in November 2021.
June 8, 2022
Ohio State Startup Feature - Entvantage DX
Entvantage DX is commercializing a proprietary collection device and bacterial assay kit as a rapid, in-office diagnostic test for differentiating viral from bacterial sinusitis. The first-of-its-kind, FDA Class II Diagnostic test kit will provide primary care and ENT physicians with a simple and accurate point-of-care test for sinusitis that takes 10 minutes to achieve results. The device has 16 issued patents in the US, Europe and Japan and four patents pending.
At the Fall Startup and Venture Capital Summit in November 2021, Joe Skraba, president and CEO, shared more on Entvantage DX's focus to address the worldwide epidemic of antibiotic overuse.
Researchers at Ohio State disclose over 300 new inventions each year across a spectrum of sectors and applications. Startups offer a compelling, flexible path to advance innovations toward commercial adoption and success. Ohio State’s 90+ startup portfolio is growing and creatively disrupting industries such as healthcare, information technology, materials, transportation, agribusiness and more producing profound change in the way we live.
